Literature DB >> 19825804

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting.

Michael M Schmidt1, K Dane Wittrup.   

Abstract

A diverse array of tumor targeting agents ranging in size from peptides to nanoparticles is currently under development for applications in cancer imaging and therapy. However, it remains largely unclear how size differences among these molecules influence their targeting properties. Here, we develop a simple, mechanistic model that can be used to understand and predict the complex interplay between molecular size, affinity, and tumor uptake. Empirical relationships between molecular radius and capillary permeability, interstitial diffusivity, available volume fraction, and plasma clearance were obtained using data in the literature. These relationships were incorporated into a compartmental model of tumor targeting using MATLAB to predict the magnitude, specificity, time dependence, and affinity dependence of tumor uptake for molecules across a broad size spectrum. In the typical size range for proteins, the model uncovers a complex trend in which intermediate-sized targeting agents (MW, approximately 25 kDa) have the lowest tumor uptake, whereas higher tumor uptake levels are achieved by smaller and larger agents. Small peptides accumulate rapidly in the tumor but require high affinity to be retained, whereas larger proteins can achieve similar retention with >100-fold weaker binding. For molecules in the size range of liposomes, the model predicts that antigen targeting will not significantly increase tumor uptake relative to untargeted molecules. All model predictions are shown to be consistent with experimental observations from published targeting studies. The results and techniques have implications for drug development, imaging, and therapeutic dosing.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19825804      PMCID: PMC4078872          DOI: 10.1158/1535-7163.MCT-09-0195

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  49 in total

1.  Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent.

Authors:  Mark S Dennis; Hongkui Jin; Debra Dugger; Renhui Yang; Leanne McFarland; Annie Ogasawara; Simon Williams; Mary J Cole; Sarajane Ross; Ralph Schwall
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

2.  [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.

Authors:  Andreas Wicki; Damian Wild; Daniel Storch; Christian Seemayer; Martin Gotthardt; Martin Behe; Stefan Kneifel; Michael J Mihatsch; Jean-Claude Reubi; Helmut R Mäcke; Gerhard Christofori
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

3.  Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging.

Authors:  Derek W Bartlett; Helen Su; Isabel J Hildebrandt; Wolfgang A Weber; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-17       Impact factor: 11.205

4.  Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts.

Authors:  Jennifer H E Baker; Kirstin E Lindquist; Lynsey A Huxham; Alastair H Kyle; Jonathan T Sy; Andrew I Minchinton
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

5.  Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.

Authors:  Frank Gu; Liangfang Zhang; Benjamin A Teply; Nina Mann; Andrew Wang; Aleksandar F Radovic-Moreno; Robert Langer; Omid C Farokhzad
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-13       Impact factor: 11.205

6.  Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability.

Authors:  Michael M Schmidt; Greg M Thurber; K Dane Wittrup
Journal:  Cancer Immunol Immunother       Date:  2008-04-12       Impact factor: 6.968

7.  Factors determining antibody distribution in tumors.

Authors:  Greg M Thurber; Michael M Schmidt; K Dane Wittrup
Journal:  Trends Pharmacol Sci       Date:  2008-01-07       Impact factor: 14.819

8.  99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.

Authors:  Torun Engfeldt; Thuy Tran; Anna Orlova; Charles Widström; Joachim Feldwisch; Lars Abrahmsen; Anders Wennborg; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-13       Impact factor: 9.236

9.  A designed ankyrin repeat protein evolved to picomolar affinity to Her2.

Authors:  Christian Zahnd; Emanuel Wyler; Jochen M Schwenk; Daniel Steiner; Michael C Lawrence; Neil M McKern; Frédéric Pecorari; Colin W Ward; Thomas O Joos; Andreas Plückthun
Journal:  J Mol Biol       Date:  2007-03-20       Impact factor: 5.469

10.  (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.

Authors:  Thuy Tran; Torun Engfeldt; Anna Orlova; Mattias Sandström; Joachim Feldwisch; Lars Abrahmsén; Anders Wennborg; Vladimir Tolmachev; Amelie Eriksson Karlström
Journal:  Bioconjug Chem       Date:  2007-10-19       Impact factor: 4.774

View more
  204 in total

1.  An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors.

Authors:  Katelyn E McCabe; Bin Liu; James D Marks; James S Tomlinson; Hong Wu; Anna M Wu
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

Review 2.  Clinical developments in nanotechnology for cancer therapy.

Authors:  Jeremy D Heidel; Mark E Davis
Journal:  Pharm Res       Date:  2010-06-12       Impact factor: 4.200

3.  Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.

Authors:  Qing Li; Christopher R So; Adrian Fegan; Vivian Cody; Mehmet Sarikaya; Daniel A Vallera; Carston R Wagner
Journal:  J Am Chem Soc       Date:  2010-11-15       Impact factor: 15.419

Review 4.  Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.

Authors:  Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-15       Impact factor: 2.745

5.  Influence of molecular size on tissue distribution of antibody fragments.

Authors:  Zhe Li; Ben-Fillippo Krippendorff; Sharad Sharma; Antje C Walz; Thierry Lavé; Dhaval K Shah
Journal:  MAbs       Date:  2015-10-23       Impact factor: 5.857

Review 6.  Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors.

Authors:  Lei Miao; C Michael Lin; Leaf Huang
Journal:  J Control Release       Date:  2015-08-12       Impact factor: 9.776

7.  mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1).

Authors:  Golnaz Kamalinia; Brian J Engel; Anupallavi Srinivasamani; Brian J Grindel; Justin N Ong; Michael A Curran; Terry T Takahashi; Steven W Millward; Richard W Roberts
Journal:  ACS Chem Biol       Date:  2020-04-30       Impact factor: 5.100

8.  A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.

Authors:  Elsje Pienaar; Nicholas A Cilfone; Philana Ling Lin; Véronique Dartois; Joshua T Mattila; J Russell Butler; JoAnne L Flynn; Denise E Kirschner; Jennifer J Linderman
Journal:  J Theor Biol       Date:  2014-12-09       Impact factor: 2.691

9.  64Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor.

Authors:  Max A Kruziki; Brett A Case; Jie Y Chan; Elizabeth J Zudock; Daniel R Woldring; Douglas Yee; Benjamin J Hackel
Journal:  Mol Pharm       Date:  2016-10-10       Impact factor: 4.939

10.  Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors.

Authors:  Greg M Thurber; Thomas Reiner; Katherine S Yang; Rainer H Kohler; Ralph Weissleder
Journal:  Mol Cancer Ther       Date:  2014-02-19       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.